Purple Biotech Reports Q2 2024 Financials and Highlights
Ticker: PPBT · Form: 6-K · Filed: Aug 16, 2024 · CIK: 1614744
Sentiment: neutral
Topics: financial-results, press-release, biotech
TL;DR
Purple Biotech dropped Q2 2024 results on Aug 16. Check financials.
AI Summary
Purple Biotech Ltd. reported its second quarter 2024 financial results and business highlights on August 16, 2024. The company, formerly known as Kitov Pharma Ltd., is based in Rehovot, Israel, and operates in the pharmaceutical preparations sector.
Why It Matters
This filing provides investors with an update on Purple Biotech's financial performance and operational progress during the second quarter of 2024.
Risk Assessment
Risk Level: low — This is a routine financial results filing with no new material events or significant financial changes disclosed.
Key Players & Entities
- Purple Biotech Ltd. (company) — Registrant
- Kitov Pharma Ltd. (company) — Former company name
- August 16, 2024 (date) — Date of press release
- Rehovot, Israel (location) — Company headquarters
FAQ
What is the primary purpose of this 6-K filing?
This 6-K filing is to report the Company's press release titled 'Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights', issued on August 16, 2024.
When did Purple Biotech Ltd. change its name from Kitov Pharma Ltd.?
The company changed its name from Kitov Pharma Ltd. on January 25, 2018.
What is Purple Biotech Ltd.'s Standard Industrial Classification code?
Purple Biotech Ltd.'s Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Where is Purple Biotech Ltd. located?
Purple Biotech Ltd.'s principal executive offices are located at 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel.
Which form does Purple Biotech Ltd. file its annual reports under?
Purple Biotech Ltd. files its annual reports under Form 20-F.
Filing Stats: 577 words · 2 min read · ~2 pages · Grade level 20 · Accepted 2024-08-16 08:14:11
Filing Documents
- ea0211551-6k_purple.htm (6-K) — 16KB
- ea021155101ex99-1_purple.htm (EX-99.1) — 146KB
- ea021155101ex99-2_purple.htm (EX-99.2) — 249KB
- 0001213900-24-069978.txt ( ) — 412KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. August 16, 2024 PURPLE BIOTECH LTD. By: /s/ Lior Fhima Lior Fhima Chief Financial Officer 2